Drug Repositioning Service Market Report 2026

Drug Repositioning Service Market Overview

• Drug Repositioning Service market size has reached to $34.2 billion in 2025 • Expected to grow to $45.92 billion in 2030 at a compound annual growth rate (CAGR) of 6.1% • Growth Driver: Surge In Rise In Healthcare Expenditures Fueling The Growth Of The Market Due To Increasing Medical Costs • Market Trend: AI-Enabled Drug Repositioning Project • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the drug repositioning service market include: • Generic Drugs (Segmentation By Type) → Expected gain of $7.95 Billion • Clinical Trial Failed Drugs (Segmentation By Type) → Expected gain of $3.78 Billion

What Is Covered Under Drug Repositioning Service Market?

Drug repositioning service involves systematically identifying new therapeutic uses for existing drugs, which allows pharmaceutical companies to maximize the value of their existing drug portfolios while minimizing the risks associated with developing entirely new compounds. Drug repositioning service leveraging existing clinical data and research, these services help streamline the drug development process, significantly reducing the time and cost required to bring effective treatments to patients. The main types of drug repositioning service are generic drugs, and clinical trial failed drugs. Generic drugs are medications that have the same active ingredients, strength, dosage form, and therapeutic effect as brand-name drugs but are typically sold at lower prices. The various therapeutic area include oncology, neurology, infectious diseases, cardiovascular diseases, other therapeutic area. These are used by various end users such as pharmaceutical companies, biotechnology firms, contract research organizations (CROs), academic research institutions, hospitals and ambulatory surgical centers.

What Is The Drug Repositioning Service Market Growth Forecast?

The drug repositioning service market size is expected to see strong growth in the next few years. It will grow to $45.92 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing demand for cost-efficient drug development, rising adoption of ai-driven discovery tools, growing focus on rare and orphan diseases, expansion of data-driven clinical research, increasing regulatory acceptance of repurposed drugs. Major trends in the forecast period include increasing use of ai-based drug repurposing platforms, rising focus on failed clinical drug re-evaluation, growing integration of real-world evidence in drug discovery, expansion of precision medicine-oriented repositioning, enhanced collaboration between pharma and cros.

What Is The Driver Of The Drug Repositioning Service Market?

The rise in healthcare expenditures is expected to propel the growth of the drug repositioning service market going forward. Healthcare expenditures refer to the total funds spent on health services, including prevention, treatment, rehabilitation, and administration. Healthcare expenditures are rising primarily due to increasing medical costs driven by technological advancements and the growing demand for healthcare services. Higher healthcare expenditure benefits drug repositioning services because increased funding allows for more clinical trials and research, accelerating the identification of new therapeutic uses for existing drugs. For instance, In May 2024, according to, Office for National Statistics, UK-based Government department, Total healthcare expenditure experienced a significant rise of 5.6% in nominal terms from 2022 to 2023. Therefore, the rise in healthcare expenditures is driving the growth of the drug repositioning service industry.

How Will The Drivers Impact Growth In The Global Drug Repositioning Service Market?

• Increasing Pressure To Reduce Drug Development Timelines And Costs (High) – During the forecast period, the increasing pressure to reduce drug development timelines and costs is expected to become a key growth driver for the drug repositioning service market by 2030. The need to shorten development cycles and control r&d expenses is accelerating demand for repositioning services, as conventional drug discovery is highly expensive and often exceeds a decade in duration. Drug repositioning enables companies to bypass early-stage discovery by leveraging existing compounds with established safety profiles, significantly reducing costs and accelerating time-to-market. It also supports faster responses to urgent and unmet medical needs. • Growing Interest In Personalized Medicine Approaches (Medium) – During the forecast period, the growing interest in personalized medicine approaches is expected to emerge as a major factor driving the expansion of the drug repositioning service market by 2030. Increasing focus on precision medicine is enhancing demand for repositioning strategies, as approved or investigational drugs can be aligned with specific genetic markers or disease subtypes. This facilitates targeted and effective therapies without initiating entirely new development programs. Repositioning enables quicker adaptation of known compounds for defined patient populations, closely supporting personalized treatment objectives. • Rise in healthcare expenditures globally supporting pharmaceutical investments (Medium) – During the forecast period, the rise in healthcare expenditures globally supporting pharmaceutical investments is expected to act as a key growth catalyst for the drug repositioning service market by 2030. Growing public and private healthcare spending is increasing investment in innovative and cost-efficient r&d strategies, including drug repositioning. As funding for healthcare systems expands, pharmaceutical companies are prioritizing faster and lower-risk development pathways. Drug repositioning offers an efficient alternative by reducing development uncertainty and financial burden, thereby strengthening its adoption.

How Will The Restraints Impact Growth In The Global Drug Repositioning Service Market?

• Intellectual property and patent protection challenges (High) – During the forecast period, the intellectual property and patent protection challenges act as a key restraint in the drug repositioning service market because repurposed drugs often lack strong patent coverage. This makes it difficult for companies to secure exclusive rights and recover investment costs. The limited ability to protect repositioned drugs discourages some pharmaceutical firms from pursuing them aggressively. Legal and regulatory complexities further add to the risk. • Scientific complexities (High) – During the forecast period, the scientific complexities hinder the growth of the drug repositioning service market because identifying new therapeutic uses for existing drugs requires deep understanding of disease biology, drug mechanisms, and molecular interactions. Many repositioning efforts fail due to incomplete data or unpredictable effects in new indications. Additionally, lack of robust biomarkers and validated models makes it challenging to prove efficacy in new contexts. • Regulatory challenges (Medium) – During the forecast period, the regulatory challenges limit the growth of the drug repositioning service market because repurposed drugs often fall into gray areas of approval pathways. While safety data may exist, proving efficacy for a new indication requires additional trials and documentation, which can be costly and time-consuming. Inconsistent regulations across countries further complicate market access. This slows down development and discourages investment.

Key Players In The Global Drug Repositioning Service Market

Major companies operating in the drug repositioning service market are Recursion Pharmaceuticals Inc., Excelra, LifeArc, Cosmos Health Inc., Fios Genomics, Insilico Medicine Inc., Melior Discovery, Delta4, Acubiosys, VeriSIM Life, BioXcel Therapeutics Inc., Pharnext S.S., NuMedii, GVK Biosciences, Plex Research, Paradigm Biopharmaceuticals, BenevolentAI Limited

Global Drug Repositioning Service Market Trends and Insights

Major companies operating in the drug repositioning service market are focusing on the adoption of artificial intelligence (AI) in drug repositioning, such as computational drug repositioning systems, which systematically identify new therapeutic indications for existing drugs using AI-driven analysis of literature and biological data. A computational drug repositioning system refers to a technology-driven platform that uses artificial intelligence, machine learning, and data mining to systematically analyze existing drugs, compounds, and biological data. For instance, in November 2024, UBE and FRONTEO, Japanese-based companies, launched a co-creation project. The co-creation project offers a collaborative framework that integrates expertise from both UBE and FRONTEO to enhance drug repositioning efforts. It enables seamless interaction between dry research (data analysis) and wet research (biological testing), improving the transition from hypothesis generation to experimental validation. By leveraging FRONTEO’s AI-driven Drug Discovery AI Factory and KIBIT technology, the project systematically discovers unreported relationships between diseases and molecules.

What Are Latest Mergers And Acquisitions In The Drug Repositioning Service Market?

In January 2024, Cosmos Health Inc., a US-based healthcare group, acquired the Cloudscreen platform for Cloudpharm P.C. for an undisclosed amount. With this acquisition, Cosmos Health Inc. aims to accelerate drug repurposing efforts by leveraging Cloudscreen’s AI platform to identify new therapeutic uses for existing drugs more efficiently. Cloudpharm P.C. is a Greece-based company that offers drug repositioning services.

What Defines the Drug Repositioning Service Market?

The drug repositioning service market consists of revenues earned by entities by providing services such as target validation, pharmacovigilance support, formulation optimization, drug combination analysis, and post-marketing surveillance. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Drug Repositioning Service Market Report 2026?

The drug repositioning service market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the drug repositioning service industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.